Myelodysplastic Syndrome (MDS) Center

Myelodysplastic syndromes (MDS) is a relatively uncommon disease, with only 15-20,000 new cases being diagnosed annually so that few centers see a sufficient number of patients in order to conduct meaningful clinical trials or detailed molecular studies. Through three decades of dedication to the study and treatment of MDS, we have built a Tissue Repository with ~50,000 samples from >5,000 patients which constitutes a unique resource for interested investigators to collaborate with us on exciting new projects. MDS patients travel from all over the country to receive the most cutting edge therapies and to participate in molecular and genetic studies which sheds light on their particular form of MDS and allows for individualized therapies. In one year we accrued in excess of 100 MDS/AML patients on a variety of clinical trials. Our group has been caring for several hundred MDS patients annually for the past few decades, making it one of the largest programs in the country and results of our studies have been published in high profile journals like Nature, New England Journal of Medicine, PLoS and Blood. In addition, we have been a recognized Center of Excellence by the MDS Foundation for almost two decades. At present, a team of clinical and basic science researchers who have many years of experience in the study and treatment of MDS are working at CUMC to develop more effective therapies for these disorders.



  • Antonietta De Los Reyes, N.P.
  • Ginevra Castagna, R.N.
  • Wendy Lanier (new patient appointment)
  • Roserika Brooks (Clinical Research Coordinator)
  • John Falkenstern (CRC)
  • Fiona Yeh (CRC)


New Patient Appointments
(212) 305-5098
Physician Referral
(212) 697-9355
Brenda Vega, assistant
(212) 305-0591
NewYork-Presbyterian Operator
(212) 305-2500